Halozyme Therapeutics (NASDAQ:HALO)‘s stock had its “market perform” rating reaffirmed by equities researchers at BMO Capital Markets in a report released on Thursday. They presently have a $19.00 target price on the biopharmaceutical company’s stock, up from their previous target price of $18.00. BMO Capital Markets’ price objective points to a potential downside of 4.38% from the stock’s current price.
HALO has been the topic of several other reports. Zacks Investment Research upgraded Halozyme Therapeutics from a “hold” rating to a “buy” rating and set a $22.00 price target on the stock in a research report on Tuesday, December 12th. Barclays cut Halozyme Therapeutics from an “overweight” rating to a “hold” rating and upped their price target for the company from $16.00 to $19.00 in a research report on Wednesday, November 22nd. Canaccord Genuity upped their price target on Halozyme Therapeutics from $17.00 to $19.00 and gave the company a “buy” rating in a research report on Wednesday, November 8th. BidaskClub cut Halozyme Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, January 9th. Finally, JPMorgan Chase & Co. reiterated an “overweight” rating and set a $22.00 price target (up from $19.00) on shares of Halozyme Therapeutics in a research report on Wednesday. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and five have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average target price of $19.89.
Shares of Halozyme Therapeutics (HALO) opened at $19.87 on Thursday. Halozyme Therapeutics has a 52 week low of $11.41 and a 52 week high of $21.13. The stock has a market capitalization of $2,758.52, a PE ratio of 52.29 and a beta of 1.99. The company has a quick ratio of 3.37, a current ratio of 3.89 and a debt-to-equity ratio of 0.60.
Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings results on Tuesday, February 20th. The biopharmaceutical company reported $0.85 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.58 by $0.27. Halozyme Therapeutics had a return on equity of 89.83% and a net margin of 19.89%. The firm had revenue of $189.60 million for the quarter, compared to analysts’ expectations of $173.11 million. During the same period in the prior year, the business posted ($0.21) earnings per share. The company’s revenue was up 386.2% on a year-over-year basis. equities analysts anticipate that Halozyme Therapeutics will post -0.72 earnings per share for the current fiscal year.
Several hedge funds and other institutional investors have recently modified their holdings of HALO. Arrowstreet Capital Limited Partnership purchased a new position in shares of Halozyme Therapeutics during the second quarter worth about $131,000. Dynamic Technology Lab Private Ltd purchased a new position in shares of Halozyme Therapeutics during the second quarter worth about $171,000. Lido Advisors LLC purchased a new position in shares of Halozyme Therapeutics during the fourth quarter worth about $202,000. 361 Capital LLC purchased a new position in shares of Halozyme Therapeutics during the third quarter worth about $207,000. Finally, Raymond James & Associates purchased a new position in shares of Halozyme Therapeutics during the fourth quarter worth about $216,000. 81.56% of the stock is owned by institutional investors.
COPYRIGHT VIOLATION WARNING: This report was originally reported by Transcript Daily and is the sole property of of Transcript Daily. If you are viewing this report on another publication, it was illegally copied and reposted in violation of United States & international trademark & copyright laws. The legal version of this report can be viewed at https://transcriptdaily.com/2018/02/24/bmo-capital-markets-reiterates-market-perform-rating-for-halozyme-therapeutics-halo.html.
About Halozyme Therapeutics
Halozyme Therapeutics, Inc is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of human enzymes and other drug candidates. The Company’s segment also includes research and development activities and product sales of Hylenex recombinant.
Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.